Screener / SEC EDGAR /CIK 0000019584 /10-K filed Feb 27, 2026, compared with Feb 28, 2025 /Numbers from the XBRL of the 10-Ks
NYSE Health care · Home Health Care Services

Chemed Corp CHE

Compare with peers Embed
SEC comment letters, last 20 years

5 reviews of CHE's filings by SEC staff

UPLOAD and CORRESP
Reviews 5 latest letter Oct 5, 2023
Questions asked 8 each answered in the company's own letter
No closing letter 0 reviews without a letter saying the staff completed it

When the SEC's staff reviews a filing, it writes to the company with numbered questions, and the company answers each one in a letter. SEC publishes the exchange once the review is over, at least 20 business days later. A question is not an accusation; most reviews end with the company adding detail to its next filing.

How the reviews went

Every review on EDGAR, from the first staff letter to the letter that closes it

  1. 1. Staff letters 6 UPLOAD
  2. 2. Questions in them 8 numbered comments
  3. 3. Company replies 6 CORRESP
  4. 4. Reviews closed 5 of 5 closing letter

Half the closed reviews took 18 days or less from the first letter to the closing letter.

Form 10-K

2023-10-05 to 2023-10-30 · 2 questions · 2 letters from the SEC, 2 from the company
Review closed 2023-10-30
Non-GAAP measuresResults discussion (MD&A)Revenue
Management's Discussion and Analysis of Financial Condition and Results of Operations · Unaudited Consolidating Summaries and Reconciliations of Adjusted EBITDA, page 90
SEC asked
We note that you are excluding licensed healthcare retention bonuses from net income to calculate adjusted EBITDA, adjusted net income and adjusted diluted earnings per share. We further note you have continued to include this adjustment for the six-months ended June 30, 2023.
Rest of the question

Please tell us your consideration of the guidance in Question 100.01 of the Non-GAAP Financial Measures Compliance & Disclosure Interpretations.

CHE answered
The Company acknowledges the Staff’s comment and notes that management carefully considers the guidance contained in the Non-GAAP Financial Measures Compliance & Disclosures

Interpretations. The Answer to Question 100.01 states, “Presenting a non-GAAP performance measure that excludes normal, recurring cash operating expenses necessary to operate a registrant’s business is one example of a measure that could be misleading.” The Answer to Question 100.01 concludes, “The staff would view an operating expense that occurs repeatedly or occasionally, including at irregular intervals, as
Rest of the answer

recurring.”

As has been widely reported, the COVID-19 pandemic resulted in a significant exodus of workers from the workplace. This trend acutely affected the healthcare industry in the United

States. A November 2021 article in US News and World Report estimated that approximately 20% of all healthcare workers in the US left the industry during the pandemic. As a result, VITAS experienced significantly higher turnover in its employee base of licensed healthcare workers and fewer opportunities to hire replacements. This situation caused significant strain on our remaining licensed healthcare workers.

On July 1, 2022, in response to this extreme, unprecedented disruption caused by the COVID-19 pandemic, VITAS implemented a one-time retention bonus program for its licensed healthcare professionals only. An eligible employee was required to continue employment for a period of one-year from July 1st to receive the bonus. Additionally, employees hired between July 1, 2022, and June 30, 2023, were eligible if they continue employment for a one-year period from their date of hire. The expense related to the one-time retention program was recognized in our GAAP earnings over the four quarterly periods beginning on July 1, 2022, with adjustments made for turnover and new hires during that period. The amount excluded from adjusted EBITDA, adjusted net income and adjusted earnings per share only relates to the estimated cost of the retention bonus program. The payroll, fringe benefit and other costs, including on-boarding and training costs, related to eligible healthcare employees were not excluded from these non-GAAP measures for any period presented.

The facts and circumstances related to the retention bonus, along with the amount accrued during the period presented, are disclosed in the Executive Summary section of Management’s

Discussion and Analysis of Financial Condition and Results of Operation of our Annual Report on Form 10-K for the year ended December 31, 2022 (page 75). The Executive Summary section in our Form 10-Qs filed during fiscal 2023 also include discussion of the retention bonus and related amounts accrued during the period presented.

Management determined that excluding the cost associated with the retention bonus from adjusted EBITDA, adjusted net income and adjusted earnings per share was appropriate and compliant with Item 10(e) of Regulation S-K and with the guidance given in Question 100.01 of the Non-GAAP Financial Measures Compliance & Disclosures Interpretations. The program was a one-time program, limited in duration and limited in scope of employees, implemented specifically to address an issue caused by the unprecedented COVID-19 pandemic. The Company has never before instituted such a retention bonus program. The retention bonus program ended on June 30, 2023, and there are no plans by management to extend this program or implement any similar programs. It is also important to note that the Company has excluded other one-time, pandemic-related transactions from adjusted EBITDA, adjusted net income and adjusted earnings per share including $80.2 million of income the Company recognized in conjunction with a CARES Act grant received in 2020.

If a member of the Staff has any questions concerning this matter or needs additional information, please feel free to contact Brian Judkins, Vice President, Secretary and Chief Legal

Officer, or the undersigned at (513) 762-6690.

Read in the reply
In its next report

First report after the company's reply of Oct 16, 2023: 10-Q filed Oct 27, 2023 ↗, against the 10-Q filed Jul 28, 2023 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Management's Discussion and Analysis of Financial Condition and Results of Operations · Unaudited Consolidating Summaries and Reconciliations of Adjusted EBITDA, page 90
SEC asked
We note your response to our comment. The retention bonus program was implemented for your licensed healthcare professionals, who have a direct impact on revenue generation, and therefore represents cash compensation, which is a normal, recurring operating expense.
Rest of the question

As such, we request that you discontinue including this adjustment in any future presentations of your non-GAAP measures for any period presented in accordance with Rule 100(b) of Regulation G as interpreted by Question 100.01 of the Non-GAAP Financial Measures Compliance & Disclosure Interpretations, as updated December 13, 2022.

CHE answered
The Company acknowledges the Staff’s comment and notes that management carefully considers the guidance contained in the Non-GAAP Financial Measures Compliance & Disclosures Interpretations.

Reflecting the Staff’s comment, the Company did not include this adjustment as part of any non-GAAP financial measure presented in either its third quarter earnings release filed on Form 8-K on October 25, 2023 or its third quarter quarterly report on Form 10-Q filed on October 27, 2023.
Rest of the answer

We will not include this adjustment for any period presented in any future presentations of our non-GAAP financial measures.

If a member of the Staff has any questions concerning this matter or needs additional information, please feel free to contact Brian Judkins, Vice President, Secretary and Chief Legal Officer, or the undersigned at

(513) 762-6690.

Read in the reply
In its next report

First report after the company's reply of Oct 27, 2023: 10-K filed Feb 29, 2024 ↗, against the 10-K filed Feb 27, 2023 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: closing letter, 2023-10-30

Form 10-K for the year ended December 31, 2019

2020-11-16 to 2020-12-04 · 1 question · 1 letter from the SEC, 1 from the company
Review closed 2020-12-04
Executive pay
Item 13. Executive Compensation, page 27
SEC asked
We note, from the information incorporated by reference from your proxy statement, the material increase in the grant date fair value of the option awards granted to Mr. McNamara in 2019 as compared to 2018. Refer to Regulation S-K Item 402(b)(1)(v) and in future filings disclose how the company determines the amount for each element of compensation to pay, and to Item 402(b)(2)(ix) and in future filings disclose
Rest of the question

the factors considered in decisions to increase or decrease compensation materially, in each case if applicable.

CHE answered
The Company acknowledges the Staff’s comment and notes that, in determining the amount of compensation for the Company's senior executives, the Compensation/Incentive Committee (the “Compensation Committee”) takes into account numerous factors that the Company discloses in the Compensation Discussion and Analysis of its proxy statements, which include historical compensation (including base salaries, annual incentive compensation and long-term equity awards), performance of the Company as a whole (both on an absolute basis and relative to its peer group), performance of the individual
Rest of the answer

business unit for which the executive is responsible (if applicable), the compensation of the Company’s senior executives compared to its peer group and other industry data, and the overall mix of compensation for senior executives (as a whole and individually).

With respect to stock options, because the Company's practice is to grant option awards in the fourth quarter of the fiscal year, after a considerable amount of the year has elapsed and after base salaries have been determined and performance share units have been granted, in determining the size of option grants, the Compensation Committee takes into account the overall mix of compensation for each senior executive based on the Company’s results for the current year and also takes into account the senior executive's performance for the current year, and issues options to appropriately balance each senior executive's compensation in the context of the entire executive compensation program. Additionally, the Black-Scholes valuation model used to value stock options is highly dependent on the Company’s stock price. Significant variation in the stock price can lead to significant changes in the per share grant date fair value of option awards. Accordingly, grants of stock options often may vary more significantly from year to year than other elements of compensation.

In future filings, the Company will supplement its disclosure to include a discussion of these and any other relevant factors.

Read in the reply
In its next report

First report after the company's reply of Nov 30, 2020: 10-K filed Feb 26, 2021 ↗, against the 10-K filed Feb 26, 2020 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: closing letter, 2020-12-04

Form 10-K for the Year Ended December 31, 2017

2018-11-29 to 2018-12-11 · 1 question · 1 letter from the SEC, 1 from the company
Review closed 2018-12-11
Non-GAAP measuresResults discussion (MD&A)Income taxes
Management's Discussion and Analysis of Financial Condition and Results of Operations · Reconciliation of Adjusted Net Income, page 101
SEC asked
We note you present certain adjustments in your non-GAAP performance measures Adjusted Net Income and Adjusted Diluted Earnings Per Share net of income taxes both here and at page 36 of your Form 10-Q for the quarter ended September 30, 2018.
Rest of the question

Please revise to present the effect of income taxes as a separate adjustment and expand your disclosure to clearly explain how the tax effects of non-GAAP adjustments are calculated. Refer to Question 102.11 of the Non-GAAP Financial Measures Compliance and Disclosure Interpretations issued April 4, 2018.

CHE answered
We acknowledge the Staff’s comment and advise the Staff that in future reconciliations of GAAP net income to non-GAAP adjusted net income and adjusted diluted earnings per share, reconciling items will be presented before income taxes with a separate line attributable to total income taxes associated with those reconciling items. We will begin to use the revised presentation beginning with our next financial report filing, Form 10-K for the fiscal year ended December 31, 2018.
Rest of the answer

The proposed revised presentation using amounts from Form 10-K for the fiscal year ended December 31, 2017 is shown below:

CHEMED CORPORATION AND SUBSIDIARY COMPANIES

RECONCILIATION OF ADJUSTED NET INCOME

(in thousands, except per share data)(unaudited)

For the Years Ended December 31,

2017

2016

2015

Net income as reported

$

98,177

108,743

110,274

Add/(deduct) pre-tax cost of:

Litigation settlements

84,476

-

Stock option expense

10,485

8,330

5,445

Loss on sale of transportation equipment

5,266

Long-term incentive compensation

4,994

1,930

7,519

Expenses related to OIG investigation

5,194

5,260

4,974

Program closure expenses

1,138

Medicare cap sequestration adjustment

447

228

Early retirement expenses

4,491

Net expenses related to litigation settlements

213

Expenses related to securities litigation

Acquisition expenses

172

Add(deduct) tax impacts:

Tax impact of the above pre-tax adjustments (1)

(42,102

)

(7,540

(6,759

Impact of tax reform

(8,302

Excess tax benefits on stock compensation

(18,932

Adjusted net income

141,054

121,487

121,667

Diluted Earnings Per Share As Reported

Net income

5.86

6.48

6.33

Average number of shares outstanding

16,742

16,789

17,422

Adjusted Diluted Earnings Per Share

8.43

7.24

6.98

(1) The tax impact of pre-tax adjustments was calculated using the applicable effective tax rate.

The "Footnotes to Financial Statements" are integral parts of this financial information.

If a member of the Staff has any questions concerning this matter or needs additional information, he or she should contact David Williams, Executive Vice President and CFO, or the undersigned at (513) 762-6690.

Read in the reply
In its next report

First report after the company's reply of Dec 6, 2018: 10-K filed Feb 27, 2019 ↗, against the 10-K filed Feb 26, 2018 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: closing letter, 2018-12-11

Form 10-K for the Year Ended December 31, 2014

2015-10-21 to 2015-11-03 · 2 questions · 1 letter from the SEC, 1 from the company
Review closed 2015-11-03
SegmentsGoodwill and impairmentLiquidity and cash
Notes to Consolidated Financial Statements
SEC asked (1)
Summary of Significant Accounting Policies, page 49 Goodwill and Intangible Assets, page 50 1. Please expand your disclosure in future filings to include a rollfoward of goodwill for each of your segments, and in total, as required by FASB ASC 350-20-50-1. 4. Stock-Based Compensation Plans, page 55
CHE answered
to this comment, we confirm that we will include in future filings a rollforward of goodwill for each of our segments, and in total, as required by FASB ASC 350-20-5-1. The rollforward in Note 2 - Summary of Significant Accounting Policies, Goodwill and Intangible Assets of our consolidated financial statements for the year-ended December 31, 2014 would appear as follows:

The table below shows a rollforward of Goodwill, as follows:

VITAS

Roto-

Rooter

Total

Balance at December 31, 2012

$

327,926

137,906

465,832

Business combinations

524

688

1,212

Foreign currency
Rest of the answer

adjustments

-

(173)

Balance at December 31, 2013

328,450

138,421

466,871

198

(198)

Program closing

(149)

Read in the reply
Notes to Consolidated Financial Statements
SEC asked (2)
Please reconcile the total compensation cost of stock-based compensation plans disclosed in note 4 to the related amounts included in your consolidated statement of cash flows for the years ended December 31, 2014, 2013 and 2012.
CHE answered
to this comment, the reconciliation of total compensation cost of stock-based compensation plans disclosed in note 4 to the related amounts included in our consolidated statement of cash flows for the years ended December 31, 2014, 2013 and 2012, is as follows:

Years Ended December 31,

Consolidated Statement of Cash Flows Caption

2014

2013

2012

Stock options expense

4,802

6,042

8,130

Non-cash portion of long-term incentive compensation

2,569

1,301

360

Stock awards included in change in other liabilities

481

480

Stock award amortization included in depreciation and
Rest of the answer

amortization

2,471

3,045

3,004

Total compensation cost of stock-based compensation plans - Note 4

10,323

10,868

11,974

Historically, we have reported a portion of non-cash stock compensation expense related to certain restricted stock awards in the caption “Amortization” in our Consolidated Statement of Income. This classification was disclosed in paragraph 3 of Note 4 of the 2014 Form 10-K. Previously, for each annual and interim period, we evaluated this presentation under “SEC Staff Accounting Bulletin: No. 99 – Materiality” and concluded that the impact of this classification is immaterial to our interim or annual consolidated financial statements, as applicable. In making this historical determination, we evaluated quantitative and qualitative factors such as the fact that this presentation is classification only within our Consolidated Statement of Income, does not impact; income from operations, income before income taxes, net income, earnings per share, net cash provided by operating activities or our Consolidated Statement Balance Sheet, and does not impact our debt covenants or management incentive compensation.

However, beginning with the Form 10-K for the year ended December 31, 2015, we intend to:

· present the components of stock compensation expense, shown in the table above, as separate line-items within our Consolidated Statement of Cash Flows as non-cash adjustments to reconcile net income to net cash provided by operations;

record a classification adjustment, for all periods presented in our Consolidated Statement of Income to include, restricted stock award expense in selling general and administrative expense; and include the following disclosure in Note 1 to the Consolidated Financial Statements:

Classification Adjustments

We recorded classification adjustments of $2.5 million, $3.0 million and $3.0 million to decrease amortization and increase selling, general and administrative expenses in our Consolidated Statement of Income for 2014, 2013 and 2012, respectively, related to non-cash restricted stock award compensation expense. This classification adjustment does not impact income from operations, income before income taxes, net income, earnings per share, net cash provided by operating activities or our Consolidated Statement Balance Sheet. We believe the impact of the classification adjustments are immaterial to our consolidated financial statements for the current and prior periods.

The Company acknowledges the following:

the Company is responsible for the adequacy and accuracy of the disclosure in the filing;

staff comments or changes to disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to the filing; and the Company may not assert staff comments as a defense in any proceedings initiated by the Commission or any person under the Federal securities laws of the United States.

Read in the reply
In its next report

First report after the company's reply of Oct 28, 2015: 10-Q filed Oct 30, 2015 ↗, against the 10-Q filed Jul 31, 2015 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: closing letter, 2015-11-03

Form 10-K for the Year Ended December 31, 2013

2014-10-29 to 2014-11-24 · 2 questions · 1 letter from the SEC, 1 from the company
Review closed 2014-11-24
Results discussion (MD&A)Liquidity and cashInventorySegments
Liquidity and Capital Resources, page 89 · Cash Flow, page 90
SEC asked (1)
We note you have provided only summarized statements of cash flow without any discussions of your cash flows. Please provide us with, and confirm that you will include in future filings, a detailed discussion analyzing the components of the statements of cash flows (i.e. operating, investing, and financing activities) that explains the significant yearto-year variations in each line item (e.g.
Rest of the question

explain the significant change in receivables, inventories, accounts payable, etc.) for each period presented. In this regard, please ensure to include robust discussions describing and quantifying the specific effect of the significant drivers that contributed to the material changes in your operating, investing and financing cash flows. Refer to Item 303 of Regulation S-K and SEC Release No. 338350 as it relates to liquidity and capital resources for further guidance.

CHE answered
to this comment, we confirm that we will include in future filings a detailed discussion analyzing the components of the statements of cash flows (i.e. operating, investing and financing activities) that explains the significant year-to-year variations in each line item (e.g. explain the significant changes in receivables, inventories, accounts payable, etc.) for each period presented. The 2013 Form 10-K Disclosure is presented below incorporating such expanded disclosures (additions are redlined):

Excerpt from p.
Rest of the answer

90 of the December 31, 2013 Form 10-K

CASH FLOW

Our cash flows for 2013, 2012 and 2011 are summarized as follows (in millions):

For the Years Ended December 31

2013

2012

2011

Net cash provided by operating activities

$

150.8

131.8

174.3

Capital expenditures

(29.3

)

(35.3

(29.6

Operating cash after capital expenditures

121.5

96.5

144.7

Purchase of treasury stock in the open market

(92.9

(60.5

(143.9

Business combinations

(2.3

(5.9

(3.7

Dividends paid

(14.1

(13.0

(12.5

Proceeds from exercise of stock options

17.1

12.3

8.0

Increase/(decrease) in cash overdraft payable

(11.4

1.9

(0.8

Other--net

(3.0

0.2

(3.6

Increase/(decrease) in cash and cash equivalents

14.9

31.5

(11.8

2013 versus 2012 -

The net decrease in cash flows generated between 2013 and 2012 of $16.6 million is mainly the result of an increase in the purchase of treasury stock of $32.3 million (resulting in a decrease in cash flow) offset by an increase of cash provided by operating activities of $19.0 million.

In 2013, we repurchased approximately 1.4 million shares of Chemed capital stock at a weighted average price of $68.50 per share. In 2012, we repurchased approximately 900,000 shares of Chemed stock at a weighted average price of $64.87 per share. Based on our current operations and our current sources of capital, we believe we have the ability to continue our current share repurchase program into the foreseeable future.

The change in net cash provided by operating activities is mainly the result of a $35.4 million increase in cash flows related to accounts payable and other current liabilities offset by a decrease in the cash flows related to accounts receivable of $15.4 million.

The increase in accounts payable and other current liabilities is mainly the result of $20.8 million of accrued but unpaid legal settlements as of December 31, 2013 and an increase in our Medicare Cap liability of $7.0 between years. The remainder of the increase is the result of the normal timing of payments with respect to accounts payable and accrued compensation.

Significant changes in our accounts receivable balances are driven mainly by the timing of payments received from the Federal government at our VITAS subsidiary. We typically receive a payment in excess of $35 million from the Federal government for hospice services every other Friday. The timing of year end will have a significant impact on the accounts receivable at VITAS. These changes generally normalize over a two year period, as cash flow variations in one year are offset in the following year.

2012 versus 2011 –

The net change in cash flows generated between 2012 and 2011 of $43.3 million is mainly the result of an $83.4 million decrease in the purchase of treasury stock (resulting in an increase in cash flows) offset by a decrease in cash provided by operations of $42.5 million.

In 2012, we repurchased approximately 900,000 shares of Chemed capital stock at a weighted average price of $64.87 per share. In 2011, we repurchased approximately 2.6 million shares of Chemed stock at a weighted average price of $55.28 per share.

The change in net cash provided by operating activities is mainly the result of a decrease in cash flows from accounts receivable of $51.3 million offset by an increase in cash flows from accounts payable and other current liabilities of $6.4 million.

Significant changes in our accounts receivable balances are driven mainly by the timing of payments received from the Federal government at our VITAS subsidiary. We typically receive a payment in excess of $35 million from the Federal government for hospice services every other Friday. The timing of year end will have a significant impact on the accounts receivable at VITAS. These changes generally normalize over a two year period as cash flow variations in one year are offset in the following year. At December 31, 2010, the Federal government experienced a delay in processing the final hospice payment of the year resulting in unusually high VITAS’ accounts receivable. This resulted in the 2011 change in accounts receivable to be larger than normal, which distorted the timing differences seen when comparing the 2012 to 2011 cash flow.

The increase in cash flows from accounts payable and other current liabilities is the result of the normal timing of payments with respect to accounts payable and accrued compensation.

Read in the reply
In its next report

First report after the company's reply of Oct 31, 2014: 10-Q filed Nov 5, 2014 ↗, against the 10-Q filed Jul 30, 2014 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Results of Operations, page 93 · 2013 Versus 2012-Segment Results, page 96
SEC asked (2)
Please disclose in future filings the business reasons for the changes between periods in the after-tax segment earnings (loss) line item shown on page 67 for each segment, as well as Corporate. Please also quantify the incremental impact of each individual business reason discussed on the overall change in the line item. Please provide us your proposed disclosures.
Rest of the question

Refer to Item 303(a)(3) of Regulation S-K, SEC Release No. 338350 and FRR 501.04.

CHE answered
to this comment, we confirm that we will include in future filings the business reasons for the changes between periods in the after-tax segment earnings (loss) line item shown on page 67 for each segment, as well as Corporate and quantify the incremental impact of each individual business reason discussed on the overall change in the line item. The 2013 Form 10-K Disclosure is presented below incorporating such expanded disclosures (additions are redlined):

Excerpt from p.
Rest of the answer

96 of the December 31, 2013 Form 10-K

2013 Versus 2012 – Segment Results

The change in net income for 2013 versus 2012 is due to (in thousands, except percentages):

Increase/(Decrease)

Amount

Percent

VITAS

(10,433

(12

) %

Roto-Rooter

(1,662

(5

Corporate

-

(12,077

(14

VITAS’ after-tax earnings were negatively impacted in 2013 compared to 2012 by a $6.5 million after-tax charge for litigation settlements, combined with a revenue decline of 2% due to the effects of the Federal government reimbursement cut due to: sequestration beginning April 1, 2013; mix shift away from high acuity care; and an increase in the Medicare Cap charge of $8.7 million. After-tax earnings as a percent of revenue at VITAS in 2013, excluding the impact of the litigation settlements, were 8.0% as compared to 8.1% in 2012. Thus, the decline in revenue between years was essentially matched by operating expense savings, mainly in labor and related fringe benefit costs.

Roto-Rooter’s after-tax earnings were negatively impacted in 2013 compared to 2012 by a $9.6 million after-tax charge for litigation settlements, offset by a revenue increase of 1% mainly due to the effect of price increases for services performed. After-tax earnings as a percent of revenue at Roto-Rooter in 2013, excluding the impact of the litigation settlements, were 10.5% as compared to 8.5% in 2012. The improvement in after-tax income as a percent of revenue is the result of expense saving initiatives including a targeted reduction in support employees at the field level, as well as changes to the healthcare and casualty insurance programs.

After-tax Corporate expenses were essentially unchanged between years.

Excerpt from p. 98 of the December 31, 2013 Form 10-K

2012 Versus 2011 – Segment Results

The change in net income for 2012 versus 2011 is due to (in thousands, except percentages)

6,219

%

(3,974

(11

1,080

3,325

The increase in VITAS’ after-tax earnings in 2012 compared to 2011 was primarily the result of an 8% increase in revenue. The revenue increase was the result of a 2.5% Medicare reimbursement increase and a 5.5% increase due to volume and mix shift. After-tax earnings were 8.1% in both years.

The decline in Roto-Rooter’s after-tax earnings in 2012 compared to 2011 was primarily the result of a 2% decline in revenue coupled with an increase in employee health care costs. The decline in revenue was driven by a decrease in jobs performed for both residential and commercial customers. After-tax earnings as a percent of revenue was 8.5% in 2012 compared to 9.4% in 2011.

The decline in Corporate expenses, which resulted in an increase in after-tax earnings, is mainly the result of a decline in long-term incentive compensation to key executives.

The Company acknowledges the following:

· the Company is responsible for the adequacy and accuracy of the disclosure in the filing;

staff comments or changes to disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to the filing; and the Company may not assert staff comments as a defense in any proceedings initiated by the Commission or any person under the Federal securities laws of the United States.

Read in the reply
In its next report

First report after the company's reply of Oct 31, 2014: 10-Q filed Nov 5, 2014 ↗, against the 10-Q filed Jul 30, 2014 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: closing letter, 2014-11-24

Letters without questions

Other letters

UPLOAD and CORRESP
1 other letter: notices that a filing will not be reviewed, requests to declare a registration effective, and the like
  • Jun 20, 2018 · SEC: letter · 2017 Form 11-K · ROTO­ · OOTER * · PLUMBING & · DRAIN SERVICE · Receipt Acknowledged:...

From the SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), 18 letters filed since 2014-10-29. Questions and answers are matched by their numbers; topics come from words in each question. The reports are compared word for word (same form, before the first SEC letter against the first report after the company's reply). No AI.

Sources

The SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), matched question by question. No AI.

Also

Filings: the letters in the filing list.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/CHE/export.csv") into a cell.

Next in Owners and insiders:Insider trades
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.